MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT01792518

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01792518
  • EudraCT 2012-002603-17
Other papers using this trial's data
  • Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial Diabetes, obesity & metabolism, 2017-11 DOI, PubMed 28636754, PMC5655723 In the PMC Open Access subset under CC BY-NC-ND.
  • Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial Proteomics. Clinical applications, 2019-03 DOI, PubMed 30632692

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Denmark, Finland, France, Germany, Japan, Philippines, South Korea, Spain, Taiwan, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01792518. Randomized; double masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2017-03-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Linagliptin 5mg
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01792518
Content hash
418e0e9e4cd662023594874be71f7ac88973efee03bbc5ade6c5c4ffa96c7942